Timing of Melanoma Immunotherapy Could Be Key to Outcomes: Study
Source: U.S. News, March 2023
MONDAY, March 6, 2023 (HealthDay News) — A tweak in timing may make an immune-system therapy much more effective for patients undergoing surgery for advanced melanoma, a new clinical trial has found.
Researchers showed that giving the therapy — a drug called Keytruda (pembrolizumab) — both before and after surgery slashed the risk of a melanoma recurrence over the next two years. That was in comparison to the standard approach of giving the drug only after surgery.
The benefit was so substantial that experts said they expect it to change the care of such patients going forward.